Will await further investigations

Great update.

Key Points
• Source: Processes
• Conclusions/Relevance: “In this narrative review we provide an update and a critical analysis of available data on miRNAs and migraines in order to propose possible interpretations. Our main objective is to stimulate research in an area that holds promise when it comes to providing reliable biomarkers for theoretical and practical scientific advance.”
• New drugs modulating the CGRP pathways are on the market, but their high cost and drug resistance leaves an unmet need for new agents and predictive biomarkers.
• Suggested biomarkers include genetic profiles; plasma and CSF neurotransmitters (CGRP, PACAP, VIP, glutamate); cytokines’ and neuroimaging alterations, although more research is needed. There remains a need for a single predictive biomarker for migraines.
• The medical community has taken an interest in miRNAs to elucidate their epigenetic impact, as well as the use of miRNAs for diagnosis, monitoring, and prediction in pain and non-pain conditions. Specifically, miR-382-5p, miR-34a-5p, and miR-30a are all being investigated.
• “[I]t is reasonable to state that miRNAs are involved in other primary and secondary headaches, such as tension-type headache, trigeminal autonomic cephalalgias, and post-traumatic headache. Finally, further investigations are needed to confirm the association between different migraine phenotypes and miRNAs expression,” stated the authors.